COM:PROMETHEUSBIOSCIENCES
Prometheus Biosciences, Inc.
- Stock
Last Close
199.74
15/06 20:00
Market Cap
9.56B
Beta: -
Volume Today
1.79M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '14 | Dec '15 | Dec '16 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | -539.50K - | -1.05M 95.37% | ||||||
average payables | 2.40M - | 1.91M 20.30% | 1.18M - | 1.06M 10.63% | 957.50K 9.28% | |||
average receivables | 543K - | 1.08M 99.36% | 1.05M 2.63% | |||||
book value per share | 3.05 - | 5.06 65.89% | 2.46 51.36% | -1.37 155.62% | -2.82 105.74% | 7.50 366.27% | 16.64 121.76% | |
capex per share | -0.17 - | -0.13 22.89% | -0.06 51.43% | -0.01 83.77% | -0.01 42.99% | -0.04 515.03% | -0.07 83.56% | |
capex to depreciation | -5.91 - | -1.73 70.73% | -0.70 59.24% | -7.97 1,031.16% | -1.87 76.52% | -4.40 135.26% | -4.30 2.40% | |
capex to operating cash flow | 0.10 - | 0.07 27.75% | 0.03 60.77% | 0.01 49.21% | 0.01 47.29% | 0.02 145.68% | 0.02 22.60% | |
capex to revenue | -20.78 - | -0.25 - | -0.17 33.49% | -0.36 118.72% | -0.40 9.34% | |||
cash per share | 3.79 - | 4.91 29.35% | 2.81 42.83% | 0.16 94.12% | 1.57 849.73% | 8.21 424.21% | 17.13 108.64% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 322.53 - | 125.87 60.98% | 55.16 56.18% | |||||
debt to assets | 0.24 - | 0.15 35.23% | 0.21 39.79% | 0.14 33.04% | 0.33 130.36% | 0.04 - | ||
debt to equity | 0.36 - | 0.22 38.72% | 0.33 48.19% | -0.20 159.80% | -0.20 3.13% | 0.04 - | ||
dividend yield | ||||||||
earnings yield | -0.09 - | -0.14 57.80% | -0.11 21.77% | -0.04 59.10% | -0.04 2.57% | -0.07 73.99% | -0.03 58.44% | |
enterprise value | 477.39M - | 662.88M 38.85% | 1.06B 60.45% | 678.00M 36.25% | 828.42M 22.19% | 981.70M 18.50% | 4.21B 328.34% | |
enterprise value over ebitda | -12.10 - | -7.55 37.63% | -10.97 45.35% | -42.58 288.10% | -28.66 32.68% | -11.18 61.00% | -28.85 157.99% | |
ev to operating cash flow | -14.69 - | -13.05 11.20% | -11.80 9.55% | -33.57 184.41% | -29.57 11.92% | -15.46 47.72% | -34.12 120.70% | |
ev to sales | 3.18K - | 606.44 - | 674.06 11.15% | 313.74 53.45% | 617.57 96.84% | |||
free cash flow per share | -1.94 - | -2.02 4.13% | -2.41 18.91% | -0.76 68.45% | -0.82 7.47% | -2.06 152.97% | -3.10 50.32% | |
free cash flow yield | -0.08 - | -0.08 4.13% | -0.10 18.91% | -0.03 68.45% | -0.03 7.47% | -0.05 61.80% | -0.03 45.97% | |
graham net net | 2.19 - | 2.67 21.66% | 1.50 43.66% | -3.08 304.65% | -2.95 4.03% | 7.18 343.12% | 15.54 116.54% | |
graham number | 12.24 - | 19.81 61.79% | 12.22 38.32% | 5.83 52.30% | 8.25 41.58% | 22.20 169.13% | 35.55 60.13% | |
income quality | 0.81 - | 0.55 32.37% | 0.87 58.25% | 1.21 38.86% | 0.90 25.47% | 0.70 21.75% | 0.87 23.49% | |
intangibles to total assets | 0 - | 0 | 0 | 0.12 Infinity% | 0 100% | 0 | 0 | |
interest coverage | -34.93 - | -31.33 10.32% | -20.74 33.80% | -13.62 34.33% | -101.98 648.83% | 31.32 130.71% | ||
interest debt per share | 1.10 - | 1.22 10.40% | 0.89 26.78% | 0.30 66.65% | 0.63 112.52% | 0.03 95.65% | 0.61 2,129.49% | |
inventory turnover | ||||||||
invested capital | 0.36 - | 0.22 38.72% | 0.33 48.19% | -0.20 159.80% | -0.20 3.13% | 0.04 - | ||
market cap | 463.51M - | 679.14M 46.52% | 973.16M 43.29% | 682.45M 29.87% | 875.22M 28.25% | 1.24B 41.56% | 4.47B 260.62% | |
net current asset value | 41.92M - | 76.05M 81.40% | 61.71M 18.86% | -49.92M 180.89% | -99.72M 99.77% | 232.74M 333.40% | 643.35M 176.43% | |
net debt to ebitda | -0.35 - | 0.19 152.58% | -0.93 603.97% | 0.28 129.96% | 1.62 479.51% | 2.93 80.92% | 1.80 38.45% | |
net income per share | -2.18 - | -3.44 57.80% | -2.69 21.77% | -1.10 59.10% | -1.07 2.57% | -2.92 172.02% | -3.38 15.63% | |
operating cash flow per share | -1.77 - | -1.89 6.72% | -2.34 23.79% | -0.75 68.04% | -0.81 8.17% | -2.03 150.33% | -3.03 49.73% | |
payables turnover | ||||||||
receivables turnover | 1.13 - | 2.90 156.25% | 6.62 128.18% | |||||
research and ddevelopement to revenue | 203.37 - | 9.80 - | 15.58 58.95% | 19.95 28.06% | 16.57 16.93% | |||
return on tangible assets | -0.47 - | -0.47 0.55% | -0.72 51.72% | -0.67 6.28% | -0.62 7.08% | -0.34 45.16% | -0.19 45.81% | |
revenue per share | 0.01 - | 0.04 - | 0.04 14.28% | 0.10 181.19% | 0.17 67.87% | |||
roe | -0.71 - | -0.68 4.88% | -1.09 60.84% | 0.80 173.52% | 0.38 52.65% | -0.39 202.16% | -0.20 47.86% | |
roic | -0.52 - | -0.55 4.21% | -0.80 46.68% | 0.95 219.40% | 0.44 53.43% | -0.38 185.14% | -0.19 49.34% | |
sales general and administrative to revenue | 63.29 - | 5.48 - | 9.02 64.61% | 9.11 0.97% | 5.84 35.94% | |||
shareholders equity per share | 3.05 - | 5.06 65.89% | 2.46 51.36% | -1.37 155.62% | -2.82 105.74% | 7.50 366.27% | 16.64 121.76% | |
stock based compensation to revenue | 15.22 - | 0.18 - | 0.60 226.34% | 3.42 468.60% | 3.06 10.39% | |||
tangible asset value | 55.95M - | 135.99M 143.06% | 94.77M 30.31% | -43.10M 145.48% | -97.54M 126.29% | 235.16M 341.08% | 675.97M 187.46% | |
tangible book value per share | 3.05 - | 5.06 65.89% | 2.46 51.36% | -1.60 164.86% | -2.82 76.45% | 7.50 366.27% | 16.64 121.76% | |
working capital | 63.80M - | 111.45M 74.68% | 94.33M 15.36% | 5.66M 94.00% | 42.20M 645.86% | 248.94M 489.89% | 685.33M 175.30% |
All numbers in USD (except ratios and percentages)